William Healy

Dr. William Healy

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in ATS Scholar
Verified
Journal Article
Open access
ASAna Sanchez-Azofra
Ana Sanchez-Azofra
AMAtul Malhotra
Atul Malhotra
RORobert L. Owens
Robert L. Owens
WHWilliam Healy
William Healy

12 March 2025 in Current Sleep Medicine Reports
Verified
Journal Article
Closed access
PDF file
ABArjun N. Bhatt
Arjun N. Bhatt
SSSohawm Sengupta
Sohawm Sengupta
AAAli Abolhassani
Ali Abolhassani
DBDavid Brower
David Brower
CFChristy Forehand
Christy Forehand
WHWilliam Healy
William Healy

9 January 2023 in ATS Scholar
Verified
Journal Article
Open access
TWThomas P. Whitton
Thomas P. Whitton
WHWilliam Healy
William Healy

25 April 2023 in Applied Sciences
Verified
Journal Article
Open access
PDF file
AMAndrew Mixson
Andrew Mixson
JWJennifer Lynn Waller
Jennifer Lynn Waller
WBWendy Bollag
Wendy Bollag
VTVarsha Taskar
Varsha Taskar
SBStephanie L. Baer
Stephanie L. Baer
WHWilliam Healy
William Healy
Increased risk of all-cause mortality not accounted for by traditional cardiovascular risk factors has been linked to chronic kidney disease. This study tested the hypothesis that mortality may be greater in patients with end-stage renal disease (ESRD) and a sleep disorder diagnosis. The United States Renal Data System database was queried to determine the effect of sleep disorder diagnoses on mortality in ESRD patients enrolled between 2004 and 2015. Sleep disorders were identified using International Classification of Diseases-9 and -10 codes. Mortality risk associated with sleep disorders was examined using Cox proportional hazards (CPH) modeling. In the final CPH model, sleep disorder diagnoses were associated with decreased risk of mortality, with hazard ratios (and 95% confidence intervals) for insomnia, hypersomnolence, restless leg syndrome, and obstructive/central sleep apnea of 0.76 (0.75–0.76), 0.81 (0.78–0.84), 0.79 (0.77–0.80), and 0.82 (0.81–0.82), respectively. Black or other race and Hispanic ethnicity, and to a small extent, female sex and increasing Charlson comorbidity index, were also associated with decreased risk, whereas increasing age, hemodialysis (versus peritoneal dialysis) and catheter or graft access type were associated with increased risk. This study suggests that the diagnosis of a sleep disorder may be associated with improved survival in ESRD patients.

25 January 2024 in Current Sleep Medicine Reports
Verified
Journal Article
Closed access
PDF file
ABArjun Bhatt
Arjun Bhatt
MAMohammad Umair Azam
Mohammad Umair Azam
RMRohit Munagala
Rohit Munagala
NZNicola Zetola
Nicola Zetola
YCYeilim Cho
Yeilim Cho
WHWilliam Healy
William Healy

NJNikhil Jaganathan
Nikhil Jaganathan
YKYounghoon Kwon
Younghoon Kwon
WHWilliam Healy
William Healy
VTVarsha Taskar
Varsha Taskar
Obstructive sleep apnea (OSA) is a prevalent pathology with current modalities of treatment including continuous positive airway pressure (CPAP), surgery, weight loss, hypoglossal nerve stimulation, and pharmacotherapy. While CPAP is the current standard treatment for OSA, lack of tolerance and side effects necessitate alternative modalities of treatment. Various pharmacologic agents exist with mechanisms that may target OSA. Early trials have demonstrated efficacy of noradrenergic-antimuscarinic combinations to stimulate the airway, promote pharyngeal muscle tone, and prevent airway collapse. These agents, which we discuss in detail, have demonstrated significant reductions in apnea-hypopnea index (AHI) and lowest oxygen saturations based on preliminary studies. Glucagon-like peptide 1 receptor agonists (GLP-1RA), which stimulate endogenous insulin, reducing glucagon release, and decreasing gastric emptying, have shown positive results for OSA patients through weight loss with reductions in AHI. In this narrative review article, we highlight the mechanisms, current data, and future potential for multiple drug classes, including respiratory stimulants and GLP-1RAs.